Novel derivatives of 1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) with improved fluorescent and σ receptors binding properties.
Despite the promising potentials of σ2 receptors in cancer therapy and diagnosis, there are still ambiguities related to the nature and physiological role of the σ2 protein. With the aim of providing potent and reliable tools to be used in σ2 receptor research, we developed a novel series of fluorescent σ2 ligands on the basis of our previous work, where high-affinity σ2 ligand 1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)-n-propyl]piperazine (1, PB28) was used as the pharmacophore. Compared to the previous compounds, these novel ligands displayed improved fluorescence and σ2 binding properties, were σ2-specifically taken up by breast tumor cells, and were successfully employed in confocal microscopy. Compound 14, which was the best compromise between pharmacological and fluorescent properties, was successfully employed in flow cytometry, demonstrating its potential to be used as a tool in nonradioactive binding assays for studying the affinity of putative σ2 receptor ligands.
Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari ALDO MORO , Via Orabona 4, I-70125 Bari, Italy.
Carmen
C
Abate
Mauro
M
Niso
Roberta
R
Marottoli
Chiara
C
Riganti
Dario
D
Ghigo
Savina
S
Ferorelli
Giulia
G
Ossato
Roberto
R
Perrone
Enza
E
Lacivita
Don C
DC
Lamb
Francesco
F
Berardi
D000818:Animals; D005434:Flow Cytometry; D005453:Fluorescence; D006168:Guinea Pigs; D006801:Humans; D008024:Ligands; D061986:MCF-7 Cells; D008297:Male; D010879:Piperazines / Q000138:chemical synthesis* / Q000378:metabolism; D051381:Rats; D017480:Receptors, sigma / Q000378:metabolism*
D008024:Ligands; C513937:PB28 compound; D010879:Piperazines; D017480:Receptors, sigma